ACCUTANE Drug Patent Profile

Which patents cover Accutane, and what generic alternatives are available?

Accutane is a drug marketed by Hoffmann La Roche and is included in one NDA.

The generic ingredient in ACCUTANE is isotretinoin. There are thirteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Accutane

A generic version of ACCUTANE was approved as isotretinoin by AMNEAL PHARMS NY on September 29^th, 2017.

Summary for ACCUTANE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	34
Patent Applications:	7,484
DailyMed Link:	ACCUTANE at DailyMed

Recent Clinical Trials for ACCUTANE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Edward Lain, MD	Phase 4
Vyne Therapeutics Inc.	Phase 4
Children's Oncology Group	Phase 2

See all ACCUTANE clinical trials

US Patents and Regulatory Information for ACCUTANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann La Roche	ACCUTANE	isotretinoin	CAPSULE;ORAL	018662-002	May 7, 1982		DISCN	Yes	No
Hoffmann La Roche	ACCUTANE	isotretinoin	CAPSULE;ORAL	018662-004	Mar 28, 1983		DISCN	Yes	No
Hoffmann La Roche	ACCUTANE	isotretinoin	CAPSULE;ORAL	018662-003	May 7, 1982		DISCN	Yes	No

Expired US Patents for ACCUTANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hoffmann La Roche	ACCUTANE	isotretinoin	CAPSULE;ORAL	018662-002	May 7, 1982
Hoffmann La Roche	ACCUTANE	isotretinoin	CAPSULE;ORAL	018662-003	May 7, 1982
Hoffmann La Roche	ACCUTANE	isotretinoin	CAPSULE;ORAL	018662-004	Mar 28, 1983
Hoffmann La Roche	ACCUTANE	isotretinoin	CAPSULE;ORAL	018662-003	May 7, 1982

International Patents for ACCUTANE

See the table below for patents covering ACCUTANE around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	53923	4-PHENOXYMETHYL-2-PHENYL-2-IMIDAZOLYL-(OR1,2,4-TRIAZOLYL)METHYL-1,3-DIOXOLANE DERIVATIVES,THEIR PREPARATION AND ANTIBACTERIAL AND ANTIFUNGAL COMPOSITIONS CONTAINING THEM
Australia	3285078
Netherlands	7801048
Italy	7847837

Market Dynamics and Financial Trajectory for Accutane

Last updated: February 26, 2026

What are the key market factors influencing Accutane (isotretinoin)?

Accutane, the brand name for isotretinoin, is a systemic retinoid primarily used to treat severe cystic acne. Market factors include regulatory restrictions, patent status, manufacturing, competition, and shifting prescribing practices.

Regulatory Environment

• FDA Approval and Restrictions: The drug has faced increased regulation due to its teratogenic effects. The iPLEDGE program, implemented in 2006, restricts pregnancy risk and enforces strict prescribing and dispensing procedures.
• Legal Actions: Multiple litigations detail concerns over adverse effects, impacting market perception and potentially influencing availability.

Patent Status and Market Exclusivity

• Patent Expiry: The original patent for Accutane expired in the U.S. in 2002. Since then, multiple generic versions entered the market.
• Market Impact: The entry of generics substantially reduced sales prices, pressuring industry revenues for the branded drug.

Manufacturing and Supply Chain

• Drug Supply: Manufacturing involves complex chemical synthesis. Any supply disruptions or quality issues can impact market availability.

Competition

• Generic Alternatives: Widely available generics dominate prescribing, reducing brand market share.
• Alternative Therapies: New acne treatments, including topical and biologic options, shift prescribing trends away from isotretinoin.

Prescribing Practices and Market Adoption

• Rising Use of Rotational Therapy: Clinicians prefer combination approaches, possibly reducing reliance on isotretinoin.
• Patient Demographics: Most prescriptions target adolescents and young adults, with some increase in adult prescriptions.

How has the financial trajectory evolved?

Accutane's sales trend reflects the interplay of regulatory restrictions, generics, and market shifts:

Year	Estimated U.S. Sales (USD Millions)	Remarks
2000	635	Peak pre-patent expiry period
2002	400	Post-patent expiry, generic entry impacts sales
2010	150	Continued generic penetration, reduced sales
2020	50	Further decline, alternative therapies gain ground

• Revenue Decline: Since patent expiry, revenues decreased markedly. Premium pricing for brand name is no longer sustainable due to generics.
• Market Share: The branded product's market share in acne therapy dropped sharply after 2002.

Are there opportunities or risks ahead?

Opportunities:

• Patent Restoration or New Formulations: Limited; no current strategies announced.
• Expanded Indications: Some research explores isotretinoin’s efficacy for other dermatological conditions. These could stimulate market growth if approved.

Risks:

• Legal Challenges: Ongoing litigation and liability concerns could deter manufacturer investment.
• Regulatory Constraints: Tight regulations and risk management programs limit prescribing flexibility.
• Market Competition: Continued dominance of generics and innovative therapies threaten market share.

Summary of Market and Financial Trends

Aspect	Status
Revenue Trend	Declining since 2002 due to generic competition
Regulatory Impact	Strict prescription controls reduce usage
Market Share	Branded Accutane holds minor segment post-2002
Growth prospects	Limited without new formulations or indications
Competitive landscape	Dominated by generics and emerging treatments

Key Takeaways

• The expiration of Accutane’s patent led to significant generic market penetration, pushing revenues downward.
• Regulatory restrictions, particularly pregnancy-related safety protocols, limit prescribing flexibility.
• The market faces long-term decline unless new indications or formulations arise.
• Competition from generics and newer therapies constrains pricing power of the brand.
• Legal liabilities and public perception of adverse effects continue to influence market dynamics.

FAQs

Q1: What is the primary factor causing revenue decline for Accutane?
A1: The entry of generic versions after patent expiry significantly reduced brand sales and market share.

Q2: How do regulatory restrictions affect Accutane’s market?
A2: The iPLEDGE program limits prescribing and dispensing, decreasing overall usage due to increased administrative hurdles.

Q3: Are there any new formulations of isotretinoin under development?
A3: Currently, no new formulations or formulations with extended patents are in advanced development.

Q4: Can legal liabilities impact Accutane’s market?
A4: Yes, ongoing lawsuits related to adverse effects pose risks to market stability and manufacturer investment.

Q5: What alternative treatments threaten Accutane’s market position?
A5: Topical therapies, biologics, and other systemic medications for acne are gaining traction, reducing reliance on isotretinoin.

References

1. U.S. Food and Drug Administration. (2020). Accutane (Isotretinoin) information.
2. IMS Health. (2010). Pharmaceutical sales data.
3. MarketWatch. (2022). Generic drug market analysis.
4. FDA. (2006). iPLEDGE program implementation.
5. American Academy of Dermatology. (2019). Acne treatment updates.